Key result
Higher CALLY index is linked to ~13% lower odds of post-PCI CA-AKI in STEMI.
Why the study?
The C-reactive protein-albumin-lymphocyte (CALLY) index and systemic immune-inflammation index (SII) had not been directly compared for predicting contrast-associated acute kidney injury (CA-AKI) after primary PCI for STEMI, nor had the incremental value of CALLY over a standard clinical risk model been evaluated.
Does the admission C-reactive protein-albumin-lymphocyte (CALLY) index predict contrast-associated acute kidney injury independently of the systemic immune-inflammation index (SII) and improve risk reclassification in STEMI patients undergoing primary PCI?
Cohort (n=1,561)
Does the admission C-reactive protein-albumin-lymphocyte (CALLY) index predict contrast-associated acute kidney injury independently of the systemic immune-inflammation index (SII) and improve risk reclassification in STEMI patients undergoing primary PCI?
In STEMI patients undergoing primary PCI, a low admission CALLY index independently predicts contrast-associated acute kidney injury outperforming SII and significantly improves patient risk reclassification when added to a clinical risk model.
Answers are grounded in this paper and cite their sources.
CALLY may refine CA-AKI risk assessment in STEMI; leaves open incremental utility over clinical models in prospective validation.
BACKGROUND: Many blood-based inflammatory and nutritional indices have been linked to contrast-associated acute kidney injury (CA-AKI) after primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), but they are rarely compared with one another or tested for what they add to existing risk models. The C-reactive protein-albumin-lymphocyte (CALLY) index and the systemic immune-inflammation index (SII) both come from routine admission blood tests, yet no study has compared them directly for CA-AKI or asked whether CALLY adds anything to a standard clinical model. AIMS: We tested whether CALLY predicts CA-AKI independently of SII in STEMI, and whether it improves reclassification and net benefit on top of a full clinical model. METHODS: In this retrospective cohort study, we reviewed 1561 consecutive STEMI patients treated with primary PCI between 2021 and 2025. CA-AKI was defined by the KDIGO 48-h criterion (creatinine rise ≥ 0.3 mg/dL), with creatinine measured daily in every patient. CALLY and ln(SII) were added, alone and together, to a prespecified clinical risk model. Models were compared with the DeLong test, continuous NRI, IDI, and decision-curve analysis. RESULTS: CA-AKI developed in 317 patients (20.3%). CALLY discriminated CA-AKI better than ln(SII) (AUC 0.632 vs. 0.559; DeLong p = 0.0003). When both were entered together, CALLY stayed independent (OR 0.872, 95% CI 0.783-0.970; p = 0.012), but ln(SII) did not (p = 0.145), even though SII was independent on its own. Adding CALLY produced only a small change in the C-statistic (0.752-0.762; DeLong non-significant), yet it improved reclassification (IDI 0.007, p = 0.003; NRI 0.166, p = 0.005) and net benefit, and calibration remained adequate (Hosmer-Lemeshow p ≥ 0.249). CONCLUSION: In STEMI patients undergoing primary PCI, a low CALLY index was independently associated with CA-AKI and improved risk reclassification when added to a clinical model, whereas SII was not independent once CALLY was included. This is the first comparison of CALLY and SII for CA-AKI, and the first assessment of CALLY for CA-AKI in STEMI.
No takes yet. Share an insight, caveat, or question.
Pamuk et al. (2026) conducted a cohort in ST-Segment Elevation Myocardial Infarction (STEMI) (n=1,561). Admission C-reactive protein-albumin-lymphocyte (CALLY) index vs. Systemic immune-inflammation index (SII) and standard clinical risk model was evaluated on Contrast-associated acute kidney injury (CA-AKI) defined by KDIGO 48-h criterion (creatinine rise ≥ 0.3 mg/dL) (OR 0.872, 95% CI 0.783-0.970, p=0.012). The CALLY index independently predicted CA-AKI after primary PCI for STEMI and outperformed SII in discrimination.
Synapse has enriched 10 related papers. Consider them for comparative context: